|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0900 - 0.0900|
|52 Week Range||0.0400 - 0.6550|
|Beta (5Y Monthly)||5.36|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 01, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Third Quarter 2020 Highlights * Total Net Revenue of $678,050 * Achieved Gross Profit of $114,529 * Continuation of Sales & Marketing Buildout * Alibaba Storefront LaunchDELRAY BEACH, FL / ACCESSWIRE / November 19, 2020 / Exactus, Inc.
Second Quarter 2020 Highlights * Total Net Revenue of $531,240 * Continuation of Sales & Marketing Buildout * White Label Division Launch * European Sales Expansion * Strengthened the Balance SheetDELRAY BEACH, Fla., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Exactus, Inc. (OTCQB: EXDI) (the “Company”) a leading supplier of hemp-derived ingredients (CBD/CBG) and feminized hemp genetics, reported its financial results for the second quarter 2020 and conference call dial-in information.During the second quarter of 2020, Exactus continued to generate year over year revenue growth through a time of pandemic.Focusing on core competencies of bulk raw ingredients, the company has built a solid pipeline of potential opportunities and has been successful in selling into the European market.The company has continued to attract top talent with the additions Daniel Alberttis as Chief Operating Officer, Mark Alouf as Director of Sales, and recruited Sonya Bain as Sales Manager and Product Specialist to facilitate the growth and manage large scale accounts.With these additions, the Company will be directing its efforts to specialty ingredients, and white label business to expand its customer base and leverage its relationships to drive more profitable and scalable revenue.Emiliano Aloi, Interim CEO of Exactus stated, "We are happy to see that our strategic shift is bringing fundamental and tangible results. Our board and management team have worked closely and diligently to achieve this transition. We feel that we are coming together as a company and bringing forth the solutions that our clients and shareholders want. Our year over year sales are up, our burn is down, and our debt is shrinking. Specifically, we are very proud of our new integrated CRM, sales, and E-commerce integration that Mark Alouf and his team have put together, and of Sonya Bain’s leadership in launching our white label division. These are the results that we need to strengthen our position in the market and to enable Exactus to engage in its M&A growth strategy.”Second Quarter 2020 Financial SummaryTotal net revenue for the second quarter 2020 was $531,240 versus $139,683 in the prior year. The increase in revenue was primarily attributable to the build out of sales and marketing. Net loss for the quarter was -$1,529,070 versus -$955,226 million in the prior year. The net loss for the second quarter 2020 was due, primarily, to non-cash expenses for stock-based compensation.Conference CallManagement will hold a conference call on Thursday, August 20, 2020 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its second quarter 2020 results and its business outlook. To access this call, dial 1-877-451-6152 (domestic) or 1-201-389-0879 (international). The conference ID is 13708862.Following the conference call, a replay will be available at 1-844-512-2921 (domestic) or 1-412-317-6671 (international). The replay passcode is 13708862.The conference call will be broadcast and available for replay on the investor relations section of the Exactus’ website and at http://public.viavid.com/index.php?id=141347.To learn more about Exactus, Inc., visit the website at www.exactushemp.com.About Exactus: Exactus Inc. (OTCQB:EXDI) is a leading producer and supplier of hemp-derived ingredients and feminized hemp genetics. Exactus is committed to creating a positive impact on society and the environment promoting sustainable agricultural practices. Exactus specializes in hemp-derived ingredients (CBD/CBG/CBC/CBN) and feminized seeds that meet the highest standards of quality and traceability. Through research and development, the Company continues to stay ahead of market trends and regulations. Exactus is at the forefront of product development for the beverage, food, pets, cosmetics, wellness, and pharmaceutical industries.For more information about Exactus: www.exactushemp.com.Investor Notice: Investing in our securities involves a high degree of risk. Before making an investment decision, you should carefully consider the risks, uncertainties and forward-looking statements described under "Risk Factors" in Item 1A of our most recent Form 10-K for the fiscal year ended December 31, 2019 filed with the Securities and Exchange Commission (the "SEC") on May 22, 2020, and in other periodic and current reports we file with the SEC. If any of these risks were to occur, our business, financial condition, or results of operations would likely suffer. In that event, the value of our securities could decline, and you could lose part or all of your investment. The risks and uncertainties we describe are not the only ones facing us. Additional risks not presently known to us or that we currently deem immaterial may also impair our business operations. In addition, our past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results in the future. See "Safe Harbor" below.Safe Harbor - Forward-Looking Statements: The information provided in this press release may include forward-looking statements relating to future events or the future financial performance of Exactus, including statements concerning harvest expectations, the impact of Exactus’ acquisition of Green Goddess, LeVor Collection, and interests in the 2019 harvest on its supply and product line expansion, Exactus’ ability to monetize its harvest, Exactus’ ability to expand its product lines and brands, the amount of future orders for Exactus products, and Exactus’ future revenue, gross margins and working capital. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "anticipates," "plans," "expects," "intends," "will," "potential," "hope" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon current expectations of Exactus and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to Exactus may be found in Exactus’ periodic and current filings with the SEC, including the factors described in the sections entitled "Risk Factors", copies of which may be obtained from the SEC's website at www.sec.gov. Any forward-looking statement speaks only as of the date on which such statement is made, and Exactus does not intend to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise.Exactus Contact:Andrew Johnson Chief Strategy Officer Exactus Inc. 509-999-9695 email@example.com Condensed Balance Sheets (Unaudited) - USD ($)Jun. 30, 2020Dec. 31, 2019 Current Assets: Cash and cash equivalents $298,754 $18,405 Accounts receivable, net 42,895 55,725 Accounts receivable - related party 107,660 18,860 Inventory 340,528 1,337,809 Prepaid expenses and other current assets - current 60,114 248,776 Prepaid expenses and other current assets - related party - current 622,159 622,160 Due from related parties 0 127,500 Total current assets 1,472,110 2,429,235 Other Assets: Deposits 0 80,000 Prepaid expenses and other current assets - long term 9,589 0 Prepaid expenses and other current assets - related party - long-term 2,175,000 2,492,045 Property and equipment, net 405,775 477,433 Intangible assets, net 1,656,894 2,147,311 Operating lease right-of-use assets, net 310,694 390,810 Total other assets 4,557,952 5,587,599 TOTAL ASSETS 6,030,062 8,016,834 Current Liabilities: Accounts payable 2,026,841 1,442,409 Accounts payable - related party 454,511 454,511 Accrued expenses 589,148 238,010 Unearned revenue -related party 0 215,000 Notes payable - current portion 90,755 0 Note payable - related parties 78,017 55,556 Subscription payable 250,000 250,000 Convertible notes, net of discounts 575,979 85,906 Derivative liability 468,387 880,410 Interest payable 39,332 16,677 Due to related party 84,500 0 Operating lease liabilities, current portion 178,541 169,869 Total current liabilities 4,836,011 3,808,348 Long Term Liabilities: Convertible notes payable 0 100,000 Notes payable - long-term portion 244,755 0 Operating lease liabilities, long-term portion 132,154 220,942 Total long term liabilities 376,909 320,942 TOTAL LIABILITIES 5,212,920 4,129,290 Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)3 Months Ended6 Months Ended Jun. 30, 2020Jun. 30, 2019Jun. 30, 2020Jun. 30, 2019 Income Statement Net revenues$531,240 $99,164 $1,051,440 $115,144 Net revenues - related party 0 40,519 315,800 40,519 Net revenues 531,240 139,683 1,367,240 155,663 Cost of sales 562,270 0 1,604,743 0 Cost of sales - related party 60,000 103,187 417,783 115,787 Total cost of sales 622,270 103,187 2,022,526 115,787 Gross profit (loss) (91,030) 36,496 (655,286) 39,876 Operating Expenses: General and administration 760,306 622,079 1,820,893 1,274,288 Selling and marketing expenses 132,110 176,602 413,000 228,480 Professional and consulting 552,197 330,891 1,280,068 2,211,038 Research and development 0 11,975 0 26,975 Total operating expenses 1,444,613 1,141,547 3,513,961 3,740,781 Loss from Operations (1,535,643) (1,105,051) (4,169,247) (3,700,905) Other Income (Expenses): Derivative gain (loss) 249,982 0 356,468 (1,454,729) Gain on extinguishment of debt, net 39,142 0 39,142 0 (Loss) gain on settlement of debt, net (16,500) 0 (23,000) 3,007,629 Interest expense (420,675) (2,519) (709,141) (369,432) Total Other Income (Expenses), net (148,051) (2,519) (336,531) 1,183,468 Loss Before Provision for Income Taxes (1,683,694) (1,107,570) (4,505,778) (2,517,437) Provision for income tax 0 0 0 0 Net Loss (1,683,694) (1,107,570) (4,505,778) (2,517,437) Net Loss attributable to non-controlling interest 154,624 152,344 310,443 187,948 Net Loss Attributable to Exactus, Inc. (1,529,070) (955,226) (4,195,335) (2,329,489) Deemed dividend on Preferred Stock 0 0 0 (904,450) Net Loss available to Exactus, Inc. common stockholders$(1,529,070) $(955,226) $(4,195,335) $(3,233,939) Net Loss per Common Share - Basic and Diluted$(0.03) $(0.03) $(0.10) $(0.09) Net Loss attributable to non-controlling interest per Common Share - Basic and Diluted 0 0 (0.01) (0.01) Net Loss available to Exactus, Inc. common stockholders per Common Share - Basic and Diluted$(0.03) $(0.03) $(0.09) $(0.12) Weighted Average Number of Common Shares Outstanding: Basic and Diluted 48,203,183 35,203,356 46,757,076 27,227,822 Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)6 Months Ended Jun. 30, 2020Jun. 30, 2019 Cash Flows From Operating Activities: Net loss$(4,505,778) $(2,517,437) Adjustments to reconcile net loss to cash used in operations: Depreciation 53,787 11,851 Derivative (gain) loss (356,468) 1,454,729 Gain on extinguishment of debt, net (39,142) 0 Stock-based compensation 1,023,303 2,083,638 Bad debt expense 51,470 0 Impairment expense 57,871 0 Inventory reserve 660,000 0 Amortization of prepaid stock-based expenses 378,138 0 Amortization of discount and debt issuance costs for convertible notes 579,115 339,806 Amortization of intangible assets 490,417 299,355 Amortization of operating lease right-of-use assets 80,116 0 Non-cash interest expense 90,000 0 Loss (gain) on settlement of debt 23,000 (3,007,629) (Increase) decrease in operating assets: Accounts receivable (38,640) (69,914) Accounts receivable - related party (88,800) (40,519) Inventory 337,281 (1,047,781) Advance to supplier - related party 0 (820,108) Prepaid expenses and other current assets - current 127,570 (289,227) Prepaid expenses and other current assets - long term (9,589) 0 Deposit 40,000 0 Increase (decrease) in operating liabilities: Accounts payable 561,432 105,400 Accounts payable - related party 0 6,762 Accrued expenses 351,138 0 Unearned revenues (215,000) 0 Interest payable 28,815 6,746 Operating lease liabilities (80,116) 0 Net Cash Used In Operating Activities (400,080) (3,484,328) Cash Flows From Investing Activities: Purchase of membership interest in subsidiary 0 (1,000,000) Purchase of property and equipment 0 (385,382) Net Cash Used In Investing Activities 0 (1,385,382) Cash Flows From Financing Activities: Advances from related party 97,000 30,000 Repayments on related party advances (12,500) 0 Proceeds from sale of Common Stock 350,000 5,478,838 Payments of principal on notes payable 0 (11,129) Proceeds from issuance of notes payable 355,929 14,229 Payments of principal on convertible notes (110,000) (186,443) Proceeds from issuance of convertible notes, net of issuance cost 0 206,900 Net Cash Provided By Financing Activities 680,429 5,532,395 Net increase in cash and cash equivalents 280,349 662,685 Cash and cash equivalents at beginning of period 18,405 1,960 Cash and cash equivalents at end of period 298,754 664,645 Supplemental Cash Flow Information: Cash paid for interest and finance charges 11,211 22,890 Cash paid for taxes 0 0 Non-Cash transactions investing and financing activity: Proceeds from sale of Series A preferred stock paid directly to settle debts 0 55,090 Convertible notes and interest payable settled by Series A preferred stock issued 0 849,360 Note payable, accrued expense and interest payable settled by common stock issued 83,160 40,616 Convertible notes settled by common stock issued 0 196,000 Common stock issued for purchase of membership interest in subsidiary 0 1,440,000 Increase in intangible assets for subscription payable 0 1,650,000 Initial beneficial conversion feature and debt discount on convertible notes 0 206,910 Preferred deemed dividend 0 904,450 Operating lease right-of-use assets and operating lease liabilities recorded upon adoption of ASC 842 0 506,506 Reduction of operating lease right-of-use asset and operating lease liabilities$80,116 $39,470
Exactus, Inc. (EXDI) (the “Company”) a leading supplier of hemp-derived ingredients (CBD/CBG) and feminized hemp genetics, today reported financial results for the first quarter 2020. During the first quarter of 2020, Exactus is pleased it has reported record revenue as its investment into sales and marketing has begun to generate revenue and scale. The Company has significantly cut its monthly cash burn and has shifted its focus to rapidly generate revenue through bulk specialty ingredient sales.